Bio-rad Laboratories, Inc. (BIO) stock forecast and price target
Price $366.36 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($366.36)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $9.61 | −3.2% | $2.6B |
| Next fiscal year ends December 31, 2027 | $9.91 | +3.1% | $2.6B |
| Next quarter ends December 31, 2026 | $2.83 | +12.8% | $689M |
| Quarter after ends March 31, 2027 | $2.83 | +49.7% | $611M |
Consensus of the analysts covering Bio-rad Laboratories, updated daily. In the last 30 days 4 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 2.6% downside over 12 months. Our discounted cash flow model with moderate assumptions puts Bio-rad Laboratories’s intrinsic value about 62% below today’s market value, and it scores 2.2 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Bio-rad Laboratories stock price target?
The average 12-month target from 3 analysts is $356.67, 2.6% below the current price of $366.36 Targets range from $280.00 to $440.00.
Is Bio-rad Laboratories a buy according to analysts?
The consensus rating is “Hold” (1 strong buy, 1 hold, 1 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Bio-rad Laboratories expected to earn?
Analysts expect EPS of $9.61 for the fiscal year ending December 31, 2026 and $9.91 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.